Blood processor
Latest Bristol-Myers Squibb Company Patents:
- Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof
- Method of controlling the pink color generated during antibody manufacturing
- Antisense oligonucleotides targeting alpha-synuclein and uses thereof
- Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
- SUBSTITUTED HETEROCYCLIC COMPOUNDS
Description
FIG. 1 is a front view of the blood processor of the present invention;
FIG. 2 is a side view of the blood processor of the present invention;
FIG. 3 is a top view of the blood processor of the present invention;
FIG. 4 is a front perspective view of the blood processor of the present invention;
FIG. 5 is a rear perspective view of the blood processor of the present invention;
FIG. 6 is a bottom view of the blood processor of the present invention; and,
FIG. 7 is a rear view of the blood processor of the present invention.
Referenced Cited
Patent History
Patent number: D396289
Type: Grant
Filed: Apr 28, 1997
Date of Patent: Jul 21, 1998
Assignee: Bristol-Myers Squibb Company (New York, NY)
Inventor: Steve McGugan (Copenhagen)
Primary Examiner: Stella Reid
Attorneys: Theodore R. Furman, Jr., Stuart E. Krieger, John M. Kilcoyne
Application Number: 0/69,559
Type: Grant
Filed: Apr 28, 1997
Date of Patent: Jul 21, 1998
Assignee: Bristol-Myers Squibb Company (New York, NY)
Inventor: Steve McGugan (Copenhagen)
Primary Examiner: Stella Reid
Attorneys: Theodore R. Furman, Jr., Stuart E. Krieger, John M. Kilcoyne
Application Number: 0/69,559
Classifications
Current U.S. Class:
Hematological Or Intravenous Treatment (41) (D24/169)
International Classification: 2401;
International Classification: 2401;